BPC-157

Every statement below describes a specific published experiment in a specific model system. BPC 157 has not been approved for use in people in any jurisdiction, and nothing in this section describes or implies use in people. Note also that a large share of the BPC 157 literature originates from a single research group (Sikiric and colleagues, University of Zagreb); this is relevant when weighing the breadth of independent replication.

In vivo animal studies, tendon. In a 2003 study, rats with transected Achilles tendons were assessed after the compound was delivered by the route given in the paper. The authors reported increased load at failure and higher Young's modulus in the exposed group relative to controls, together with functional scores, increased fibroblast and collagen formation, and reduced inflammatory cell infiltration on microscopic examination (Staresinic et al., 2003, PMID 14554208).

A 2006 study used a rat Achilles-detachment model, examining tendon-to-bone repair. The authors reported that the detached junction did not repair spontaneously in that model but did show restoration in animals receiving the peptide, with improved functional and biomechanical measures, and that the aggravation produced by concurrent corticosteroid delivery was substantially reduced in the same model (Krivic et al., 2006, PMID 16583442).

In vivo animal studies, crush injury. In a 2008 study using a rat hind-limb crush-injury model, the authors reported improved repair in the exposed group on macroscopic assessment (described as less hematoma and edema), together with functional and microscopic measures and changes in creatine kinase and lactate dehydrogenase activity (Novinscak et al., 2008, PMID 18668315).

In vitro and cell culture. A 2011 study examined BPC 157 applied to cultured rat Achilles tendon fibroblasts and tendon explants. The authors reported increased tendon explant outgrowth, improved cell survival under oxidative stress, and a concentration-dependent increase in fibroblast migration, and attributed the increase in cell spreading and migration to activation of the FAK-paxillin pathway (Chang et al., 2011, PMID 21030672).

Proposed mechanisms. Angiogenic signalling is the mechanism most directly examined in the primary literature. A 2017 study combined a rat hind-limb ischemia model with cultured vascular endothelial cells of donor origin. The authors reported increased vessel density in both the in vivo and in vitro arms and faster restoration of perfusion in the ischemic limb, alongside increased mRNA and protein expression of VEGFR2, promotion of VEGFR2 internalisation, and activation of VEGFR2-Akt-eNOS signalling (Hsieh et al., 2017, PMID 27847966). The endothelial-cell work in that paper is cell culture, not delivery to a person. It is labelled as cell culture here so it cannot be misread.

Review articles have summarised the proposed relationship between BPC 157 and angiogenic signalling factors in the context of soft-tissue repair models (Gwyer, Wragg & Wilson, 2019, PMID 30915550; Seiwerth et al., 2021, PMID 34267654). These are reviews and are cited here for their characterisation of the field, not as evidence of any specific experimental result.

Limits of the current evidence base, stated plainly because it matters more to a researcher than any summary of positive findings. The published BPC 157 literature is predominantly preclinical: rodent models and cell culture. PubMed indexed 231 records for the phrase "BPC 157" as of 3 October 2026. Controlled efficacy trials in people are not established in the published literature. Absence of published adverse findings is not evidence of safety and should not be read as such. A substantial proportion of the in vivo literature originates from one research group, which limits the weight that can be placed on independent replication. Findings in a rodent injury model do not transfer to other species or contexts, and the papers above should be read as reporting on the specific models they used.